新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 肥胖 » Apollo完成对艾尔建肥胖干预业务的收购

Apollo完成对艾尔建肥胖干预业务的收购

来源:生物谷 2013-12-03 08:04

2013年12月3日讯 /生物谷BIOON/ --艾尔建(Allergan)12月2日宣布,已完成将其肥胖干预业务出售给Apollo Endosurgery公司,该业务涉及生产和销售减肥方案,包括Lap-Band可调式胃束带系统和Orebera胃内气囊系统。

Lap-Band是一种硅胶圈,通过外科手术植入胃的外周,以阻止患者吃的过多并帮助其减肥。

根据今年10月29日所达成的协议条款,艾尔建收到了一笔7500万美元的现金支付,持有Apollo价值1500万美元的股权,以及高达2000万美元的监管和销售里程碑款项。

Apollo Endosurgery是内窥镜外科手术医疗器械领域的一流开发商。随着全世界肥胖患者数目达到流行病学水平,收购Lap-band和Orbera技术,使Apollo Endosurgery能够向外科医生和患者提供创新、微创肥胖解决方案,使该公司在该领域达到了领先地位。

去年10月,报道称,由于销售额的快速下滑,以及有关患者死亡事件及前客户刑事调查的一窝蜂负面报道,艾尔建(Allergan)正在考虑出售其Lap-Band减肥单元。

根据Allergan于2012年公布的数据,Lap-Band业务已连续第5个季度下滑,2012年第三季度销售仅为3740万美元,与去年同期相比下滑25%,与2008年同期相比下滑53%。

Allergan负责人David E.I.Pyott在分析师电话会议上称,该公司正在探索肥胖干预业务的战略选择,而Lap-Band的销售力度并不适合Allergan公司高速增长的属性(profile)。(生物谷Bioon.com)

英文原文:Apollo Endosurgery Completes Acquisition of Allergan Inc.'s Obesity Intervention Division

AUSTIN, Texas, Dec. 2, 2013 /PRNewswire via COMTEX/ -- Apollo Endosurgery, Inc., a leading developer of medical devices for endoscopic surgical procedures, today announced the completion of the acquisition of the obesity intervention division of Allergan, Inc., which manufactures and sells weight loss solutions comprised of the LAP-BAND® adjustable gastric banding system and the ORBERA(TM) intra-gastric balloon system.

"With worldwide obesity numbers reaching epidemic levels, the acquisition of the LAP-BAND® and ORBERA(TM) technologies places Apollo Endosurgery in a leadership position to provide surgeons and patients with innovative and less invasive solutions in the fight against obesity," said Dennis McWilliams, President and CEO of Apollo Endosurgery. "By expanding both our product portfolio and adding talent to our team, this acquisition will be a catalyst for growth as we continue to advance technologies in the fields of bariatric and minimally invasive surgery."

About the AcquisitionApollo announced the acquisition on October 29, 2013, for a purchase price of up to $110 million. This total includes an upfront cash payment of $75 million, a minority equity interest in Apollo by Allergan of $15 million, and up to $20 million in additional contingent consideration to be paid upon achievement of certain regulatory and sales milestones.

Piper Jaffray & Co. served as exclusive financial advisor and Cooley LLP served as legal counsel to Apollo Endosurgery in connection with the transaction. Current Apollo investors PTV Sciences, H.I.G. BioVentures, Remeditex Ventures, Novo A/S and CPMG, Inc. provided the equity financing of the acquisition. Debt financing was led by Oxford Finance LLC, who was joined by MidCap Financial, LLC and EastWest Financial Services.

About Apollo Endosurgery, Inc.Apollo Endosurgery, Inc. is dedicated to revolutionizing patient care through the adoption of less invasive bariatric and endoscopic surgical solutions. Apollo Endosurgery was cofounded with the Apollo Group, a unique collaboration of physicians from the Mayo Clinic, Johns Hopkins University, Medical University of South Carolina, the University of Texas Medical Branch and the Chinese University of Hong Kong. This collaboration developed a broad portfolio of patents in the field of endoscopic surgery that became the foundation of Apollo Endosurgery.

Apollo Endosurgery, LAP-BAND, and ORBERA are trademarks of Apollo Endosurgery, Inc.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库